FHTX
Income statement / Annual
Last year (2024), Foghorn Therapeutics Inc.'s total revenue was $22.60 M,
a decrease of 33.83% from the previous year.
In 2024, Foghorn Therapeutics Inc.'s net income was -$86.62 M.
See Foghorn Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$22.60 M |
$34.16 M |
$19.23 M |
$1.32 M |
$430,000.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$109.69 M
|
$19,228.00
|
$7.52 M
|
$57.72 M
|
$1.79 M
|
$379,000.00
|
| Gross Profit |
$22.60 M
|
-$75.53 M
|
$19.21 M
|
-$6.20 M
|
-$57.29 M
|
-$1.79 M
|
-$379,000.00
|
| Gross Profit Ratio |
1
|
-2.21
|
1
|
-4.7
|
-133.22
|
0
|
0
|
| Research and Development Expenses |
$94.53 M
|
$109.69 M
|
$105.62 M
|
$80.33 M
|
$57.72 M
|
$44.36 M
|
$21.23 M
|
| General & Administrative Expenses |
$28.36 M
|
$32.37 M
|
$30.75 M
|
$21.73 M
|
$11.25 M
|
$6.72 M
|
$4.82 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$28.36 M
|
$32.37 M
|
$30.75 M
|
$21.73 M
|
$11.25 M
|
$6.72 M
|
$4.82 M
|
| Other Expenses |
$2.40 M
|
$0.00
|
$8.26 M
|
$2.49 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$125.29 M
|
$142.06 M
|
$136.37 M
|
$102.05 M
|
$68.96 M
|
$51.08 M
|
$26.05 M
|
| Cost And Expenses |
$125.29 M
|
$142.06 M
|
$136.37 M
|
$102.05 M
|
$68.96 M
|
$51.08 M
|
$26.05 M
|
| Interest Income |
$11.90 M
|
$10.88 M
|
$5.68 M
|
$2.55 M
|
$1.00 M
|
$495,000.00
|
$113,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$1.91 M
|
$979,000.00
|
$540,000.00
|
$371,000.00
|
| Depreciation & Amortization |
$3.12 M
|
$3.45 M
|
$7.90 M
|
$7.52 M
|
$5.53 M
|
$1.79 M
|
$379,000.00
|
| EBITDA |
-$97.17 M |
-$104.46 M |
-$113.82 M |
-$96.19 M |
-$66.49 M |
-$48.80 M |
-$25.59 M |
| EBITDA Ratio |
-4.3
|
-3.06
|
-6.09
|
-71.99
|
-153.96
|
0
|
0
|
| Operating Income Ratio |
-4.54
|
-3.16
|
-6.09
|
-76.37
|
-159.37
|
0
|
0
|
| Total Other Income/Expenses Net |
$16.06 M
|
$13.71 M
|
$8.26 M
|
-$586,000.00
|
-$269,000.00
|
-$44,000.00
|
-$288,000.00
|
| Income Before Tax |
-$86.62 M
|
-$94.20 M
|
-$108.88 M
|
-$101.32 M
|
-$68.80 M
|
-$51.13 M
|
-$26.34 M
|
| Income Before Tax Ratio |
-3.83
|
-2.76
|
-5.66
|
-76.82
|
-160
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$4.23 M
|
-$8,255.00
|
$1.91 M
|
$979,000.00
|
$540,000.00
|
$83,000.00
|
| Net Income |
-$86.62 M
|
-$98.43 M
|
-$108.87 M
|
-$103.23 M
|
-$69.78 M
|
-$51.67 M
|
-$26.34 M
|
| Net Income Ratio |
-3.83
|
-2.88
|
-5.66
|
-78.26
|
-162.28
|
0
|
0
|
| EPS |
-1.58 |
-2.34 |
-2.62 |
-2.78 |
-1.9 |
-1.4 |
-1.34 |
| EPS Diluted |
-1.58 |
-2.34 |
-2.62 |
-2.78 |
-1.9 |
-1.4 |
-1.34 |
| Weighted Average Shares Out |
$54.90 M
|
$41.97 M
|
$41.59 M
|
$37.17 M
|
$36.79 M
|
$36.82 M
|
$19.63 M
|
| Weighted Average Shares Out Diluted |
$54.90 M
|
$41.97 M
|
$41.59 M
|
$37.17 M
|
$36.79 M
|
$36.82 M
|
$19.63 M
|
| Link |
|
|
|
|
|
|
|
